Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 10/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906405 | 0.93 | SCN10A (0.44) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24906502 | 0.89 | SCN10A (0.48) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24757353 | 0.89 | SCN10A (0.48) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24906530 | 0.88 | SCN10A (0.47) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24906492 | 0.86 | SCN10A (0.54) | SCN10A | |
| SCHEMBL24758289 | 0.85 | SCN10A (0.45) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24906529 | 0.85 | SCN10A (0.48) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24906528 | 0.85 | SCN10A (0.48) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24758182 | 0.83 | SCN10A (0.51) | SCN10ANR1I2CACNA1CAKR1C3AKR1C2 | |
| SCHEMBL24757351 | 0.82 | CA1 (0.46) | SCN10ANR1I2CACNA1CCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | SCN10A 8/4885NR1I2 185/4885CACNA1C 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.